Trials / Terminated
TerminatedNCT00053833
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
S0025: Phase II Trial Of Irinotecan (CAMPTOSAR) For Patients With Platinum And Taxane Refractory Ovarian, Peritoneal Or Fallopian Tube Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- SWOG Cancer Research Network · Network
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have refractory ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Detailed description
OBJECTIVES: * Determine the objective confirmed and unconfirmed complete and partial response rates of patients with platinum- and taxane-refractory ovarian epithelial, primary peritoneal, or fallopian tube cancer treated with irinotecan. * Determine the progression-free and overall survival of patients treated with this drug. * Evaluate the qualitative and quantitative toxic effects of this drug in these patients. OUTLINE: Patients receive irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 3 years. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | irinotecan |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-07-01
- Completion
- 2004-07-01
- First posted
- 2003-02-06
- Last updated
- 2013-11-08
Locations
100 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00053833. Inclusion in this directory is not an endorsement.